Dear Investor,
Please find attached a press release from our partner Regeneron:
https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-review
Do not hesitate to contact us for any further questions.
With best regards,
Roche Investor Relations | |
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com |
Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Investor Relations North America | |
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Attachments
- Original document
- Permalink
Disclaimer
Roche Holding AG published this content on 14 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 October 2021 11:41:08 UTC.